Third Pole

Third Pole Therapeutics develops critical life-sustaining cardiopulmonary therapies, focusing on innovative inhaled nitric oxide (iNO) delivery systems. The company's technology generates nitric oxide on-demand by combining electricity and ambient air, eliminating the need for compressed gas cylinders. Third Pole's primary products are eNOfit, a miniaturized wearable device for home and travel use, and eNOcare, a lightweight portable in-hospital device.

The eNOfit device is designed for the ambulatory treatment of patients suffering from pulmonary hypertension associated with Interstitial Lung Disease (ILD) and Chronic Obstructive Pulmonary Disease (COPD). In February 2024, Third Pole successfully completed an early feasibility study for eNOfit under an FDA Investigational Device Exemption, validating its safe and practical use. The company plans to move forward with larger randomized placebo-controlled safety and efficacy studies.

The eNOcare platform aims to enter the existing USD 600 million nitric oxide hospital market. Third Pole expects rapid adoption and significant market expansion for eNOcare due to its reported superior safety, usability, and reliability features compared to other product alternatives.

Third Pole's technology addresses the cost and logistical challenges that have limited widespread iNO use, particularly in markets lacking the infrastructure to handle compressed gas cylinders. The company's products have the potential to capture the existing tank-based market and expand treatment options for various conditions, including ILD, COPD, cystic fibrosis, heart failure, stroke, and certain viral and bacterial infections.